Cerebrospinal Fluid and Plasma Concentrations of the Inflammatory Marker Soluble CD27 in a Large Surgical Population

Overview

Journal iScience

Publisher Cell Press

Date 2024 Jun 17

PMID 38883839

Authors

Celien Tigchelaar

Janet L Cunningham

Annica J Rasmusson

Mans Thulin

Joachim Burman

Ido P Kema

Anders Larsson

Anthony R Absalom

Affiliations

Soon will be listed here.

Abstract

Soluble CD27 (sCD27) is a potential biomarker for diseases involving immune dysfunction. As there is currently little data on cerebrospinal fluid (CSF) sCD27 concentrations in the general population we measured CSF and plasma concentrations in 486 patients (age range 18-92 years, 57% male) undergoing spinal anesthesia for elective surgery. Across the complete cohort the median [range] sCD27 concentrations were 163 [<50 to 7474] pg/mL in CSF and 4624 [1830 to >400,000] pg/mL in plasma. Plasma sCD27, age and Qalb were the factors most strongly associated with CSF sCD27 levels. Reference sCD27 concentration intervals (central 95% of values) in a sub-group without the indication of neuropsychiatric, inflammatory or systemic disease (158 patients) were <50 pg/mL - 419 pg/mL for CSF and 2344-36422 pg/mL for plasma. These data provide preliminary reference ranges that could inform future studies of the validity of sCD27 as a biomarker for neuro- and systemic inflammatory disorders.

Citing Articles

Three cases with chronic obsessive compulsive disorder report gains in wellbeing and function following rituximab treatment.

Gallwitz M, Lindqvist I, Mulder J, Rasmusson A, Larsson A, Husen E Mol Psychiatry. 2024; .

PMID: 39304742 DOI: 10.1038/s41380-024-02750-y.

References

Lee N, Jeong S, Jeon K, Park M, Song W . Prognostic impacts of soluble immune checkpoint regulators and cytokines in patients with SARS-CoV-2 infection. Front Immunol. 2022; 13:903419. PMC: 9423766. DOI: 10.3389/fimmu.2022.903419. View

Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C . Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019; 25(12):1822-1832. PMC: 7147972. DOI: 10.1038/s41591-019-0675-0. View

Kallio P, MURPHY E . Soluble CD27 in thyroid disorders. J Lab Clin Med. 1998; 132(6):478-82. DOI: 10.1016/s0022-2143(98)90125-1. View

Faul F, Erdfelder E, Lang A, Buchner A . G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007; 39(2):175-91. DOI: 10.3758/bf03193146. View

Widney D, Gundapp G, Said J, van der Meijden M, Bonavida B, Demidem A . Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol. 1999; 93(2):114-23. DOI: 10.1006/clim.1999.4782. View

Hosnijeh F, Portengen L, Spath F, Bergdahl I, Melin B, Mattiello A . Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses. Int J Cancer. 2015; 138(10):2357-67. DOI: 10.1002/ijc.29969. View

de Milito A, Aleman S, Marenzi R, Sonnerborg A, Fuchs D, Zazzi M . Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. Clin Exp Immunol. 2002; 127(3):486-94. PMC: 1906306. DOI: 10.1046/j.1365-2249.2002.01786.x. View

Hintzen R, de Jong R, Hack C, Chamuleau M, de Vries E, ten Berge I . A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. J Immunol. 1991; 147(1):29-35. View

Hintzen R, van Lier R, Kuijpers K, Baars P, Schaasberg W, Lucas C . Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 1991; 35(1-3):211-7. DOI: 10.1016/0165-5728(91)90175-7. View

10.

Bramer G . International statistical classification of diseases and related health problems. Tenth revision. World Health Stat Q. 1988; 41(1):32-6. View

11.

de Rie M, Hamerlinck F, Hintzen R, Bos J, van Lier R . Quantitation of soluble CD27, a T-cell activation antigen, and soluble interleukin-2 receptor in serum from patients with psoriasis. Arch Dermatol Res. 1991; 283(8):533-4. DOI: 10.1007/BF00371929. View

12.

Tak P, Hintzen R, Teunissen J, Smeets T, Daha M, van Lier R . Expression of the activation antigen CD27 in rheumatoid arthritis. Clin Immunol Immunopathol. 1996; 80(2):129-38. DOI: 10.1006/clin.1996.0106. View

13.

McKay H, Bream J, Margolick J, Martinez-Maza O, Phair J, Rinaldo C . Host factors associated with serologic inflammatory markers assessed using multiplex assays. Cytokine. 2016; 85:71-9. PMC: 5088708. DOI: 10.1016/j.cyto.2016.05.016. View

14.

Han B, Olsen N, Bottaro A . The CD27-CD70 pathway and pathogenesis of autoimmune disease. Semin Arthritis Rheum. 2015; 45(4):496-501. DOI: 10.1016/j.semarthrit.2015.08.001. View

15.

Kersten M, Evers L, Dellemijn P, van den Berg H, Portegies P, Hintzen R . Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. Blood. 1996; 87(5):1985-9. View

16.

Sikaris K . Physiology and its importance for reference intervals. Clin Biochem Rev. 2014; 35(1):3-14. PMC: 3961997. View

17.

Feresiadou A, Nilsson K, Ingelsson M, Press R, Kmezic I, Nygren I . Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease. J Neuroimmunol. 2019; 332:31-36. DOI: 10.1016/j.jneuroim.2019.03.015. View

18.

Ozcurumez M, Haeckel R . Biological variables influencing the estimation of reference limits. Scand J Clin Lab Invest. 2018; 78(5):337-345. DOI: 10.1080/00365513.2018.1471617. View

19.

van den Bent M, Lamers C, van t Veer M, Sillevis Smitt P, Bolhuis R, Gratama J . Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies. Ann Hematol. 2002; 81(4):187-91. DOI: 10.1007/s00277-002-0448-5. View

20.

Agematsu K, Kobata T, Yang F, Nakazawa T, Fukushima K, Kitahara M . CD27/CD70 interaction directly drives B cell IgG and IgM synthesis. Eur J Immunol. 1995; 25(10):2825-9. DOI: 10.1002/eji.1830251017. View